Zhimeng Biopharma EN | 简体
Zhimeng Biopharma
  • Home
  • About Us
  • People
    • Leadership Team
    • Management Team
    • Scientific Advisors
  • Pipeline
  • News
  • Investors
  • Join Us
  • Contact

People

Scientific Advisors

Fabien Zoulim, M.D., Ph.D.

Fabien Zoulim, M.D., Ph.D.

Pei-Jer Chen, MD, Ph.D.

Pei-Jer Chen, MD, Ph.D.

Kewei Wang, M.D., Ph.D.

Kewei Wang, M.D., Ph.D.

Get in touch

Contact Us About Us Leadership Team Management Team Scientific Advisors
Quick Links
  • About Us
  • Contact Us
  • Join Us
  • Pipeline
  • Leadership Team
  • Management Team
  • Scientific Advisors
Recent News
  • Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R Designed for the Treatment of Chronic Hepatitis B Virus Infection
  • Zhimeng Biopharma Received Approval from US FDA for Starting Clinical Trial on Its HBV Capsid Inhibitor ZM-H1505R
  • Zhimeng Biopharma Announced Completion of Series Pre-A Financing Led by Lake Capital and Shenzhen Capital Group Co., Ltd.
  • Zhimeng Biopharma announces that it will present new anti-HBV data on its novel hepatitis B virus (HBV) nucleocapsid formation inhibitor CB-001 at the EASL-AASLD Joint Meeting on HBV Endpoints in London, March 8-9, 2019

© 2020 Zhimeng Biopharma. All Rights Reserved. 备案号:沪ICP备18045542号-1 | 沪公网安备 31011502011190号

© 2020 Zhimeng Biopharma. All Rights Reserved.